Hologic, Inc. (NASDAQ:HOLX) Receives $89.50 Consensus Target Price from Analysts

Shares of Hologic, Inc. (NASDAQ:HOLX) have received a consensus recommendation of “Moderate Buy” from the fifteen research firms that are presently covering the company, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a hold recommendation, eight have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $89.50.

HOLX has been the subject of a number of recent analyst reports. StockNews.com upgraded Hologic from a “hold” rating to a “buy” rating in a research report on Thursday, November 14th. Needham & Company LLC reaffirmed a “buy” rating and set a $90.00 price objective on shares of Hologic in a research report on Thursday, December 19th. Evercore ISI increased their price objective on shares of Hologic from $78.00 to $82.00 and gave the stock an “in-line” rating in a research note on Tuesday, October 1st. Wolfe Research initiated coverage on shares of Hologic in a research report on Friday, December 13th. They issued a “peer perform” rating for the company. Finally, JPMorgan Chase & Co. increased their price target on shares of Hologic from $92.00 to $94.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 5th.

Insider Buying and Selling

In related news, COO Essex D. Mitchell sold 24,856 shares of the firm’s stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the transaction, the chief operating officer now owns 27,957 shares in the company, valued at $2,134,237.38. This trade represents a 47.06 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.75% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Hologic

Large investors have recently modified their holdings of the business. Prentiss Smith & Co. Inc. increased its holdings in Hologic by 0.3% in the third quarter. Prentiss Smith & Co. Inc. now owns 48,696 shares of the medical equipment provider’s stock valued at $3,967,000 after purchasing an additional 130 shares during the period. Covestor Ltd grew its position in shares of Hologic by 23.8% in the 3rd quarter. Covestor Ltd now owns 692 shares of the medical equipment provider’s stock valued at $56,000 after buying an additional 133 shares during the last quarter. First Horizon Advisors Inc. increased its stake in shares of Hologic by 38.3% in the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after buying an additional 134 shares during the period. Empirical Finance LLC raised its position in shares of Hologic by 1.8% during the third quarter. Empirical Finance LLC now owns 8,473 shares of the medical equipment provider’s stock worth $690,000 after acquiring an additional 147 shares during the last quarter. Finally, Wedmont Private Capital lifted its stake in shares of Hologic by 3.7% in the third quarter. Wedmont Private Capital now owns 4,519 shares of the medical equipment provider’s stock worth $361,000 after acquiring an additional 162 shares during the period. Institutional investors own 94.73% of the company’s stock.

Hologic Trading Down 0.2 %

Shares of Hologic stock opened at $72.60 on Friday. Hologic has a 52-week low of $70.36 and a 52-week high of $84.67. The stock has a market cap of $16.48 billion, a PE ratio of 21.80, a PEG ratio of 2.38 and a beta of 0.96. The firm has a 50-day moving average of $77.61 and a 200-day moving average of $78.48. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.03 and a current ratio of 3.69.

Hologic (NASDAQ:HOLX) last announced its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The firm had revenue of $987.90 million for the quarter, compared to analyst estimates of $978.25 million. During the same quarter in the prior year, the business posted $0.89 EPS. The business’s revenue was up 4.5% compared to the same quarter last year. As a group, sell-side analysts forecast that Hologic will post 4.28 EPS for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.